Where every FDA form lives in an eCTD submission, why the dynamic XFA versions break standard PDF viewers, and how form leaves behave across sequence lifecycles.
The eCTD backbone is harmonized; everything that gets submissions rejected is regional. A country-by-country guide to Module 1, DTD versions, and validation differences.
License fees are the visible part of eCTD publishing cost — and often not the biggest part. An honest breakdown of what teams actually pay across software, services, validation, and hidden line items.
Training records are among the most common GxP inspection findings — usually a systems failure, not a people failure. Here’s what training management software has to do to fix that.
A pharmaceutical EDMS in 2026 is judged on Part 11 e-signatures, audit trails, and how far it extends beyond regulatory — into quality, clinical, training, and inspection readiness.
Free eCTD viewers open a sequence. Enterprise review platforms answer the questions reviewers actually ask. Here’s what separates them — including the FDA-forms problem nobody mentions in demos.
Health authority questions are predictable — they cluster by discipline and CTD module. Teams that prepare for likely questions before submission cut review cycles and save hundreds of hours.
Agency correspondence is legally consequential, deadline-driven, and — at most companies — scattered across inboxes. Here’s what a real correspondence system of record looks like.
Most regulatory intelligence software is a firehose. The useful question is not ‘what changed?’ but ‘what changed that affects MY applications?’ — and that requires portfolio-aware scoring.
What submission planning software actually needs to do in 2026 — and how to evaluate the options, from Veeva RIM to generic project tools to purpose-built planners.
